Principal Financial Group Inc. Acquires 57,996 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Principal Financial Group Inc. raised its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 7.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 830,184 shares of the biopharmaceutical company's stock after purchasing an additional 57,996 shares during the period. Principal Financial Group Inc. owned approximately 0.53% of TG Therapeutics worth $24,989,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Blue Trust Inc. grew its position in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 849 shares in the last quarter. Synergy Asset Management LLC bought a new position in shares of TG Therapeutics during the fourth quarter valued at about $75,000. GAMMA Investing LLC raised its stake in TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 2,171 shares in the last quarter. KBC Group NV raised its stake in TG Therapeutics by 30.5% in the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company's stock worth $109,000 after buying an additional 1,092 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new stake in TG Therapeutics in the third quarter worth about $111,000. Institutional investors own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. increased their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. HC Wainwright restated a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Wednesday, January 15th. Finally, StockNews.com cut shares of TG Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, January 31st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX traded down $0.81 on Thursday, reaching $28.53. The company's stock had a trading volume of 1,700,339 shares, compared to its average volume of 2,150,958. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $36.84. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a 50-day simple moving average of $30.84 and a 200 day simple moving average of $27.97. The company has a market cap of $4.44 billion, a P/E ratio of -285.27 and a beta of 2.26.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 10.50% of the stock is currently owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.